Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer
Henry Gómez(National Cancer Center), Adrián Martín(Instituto Ramón y Cajal de Investigación Sanitaria), Michael Arbushites(Cancer Institute (WIA)), Miguel A. Chavez(GlaxoSmithKline (India)), Dinesh Chandra Doval(Rajiv Gandhi Cancer Institute and Research Centre), Tal Zaks(Moderna Therapeutics (United States)), S. Stein(GlaxoSmithKline (United Kingdom)), Michelle Casey(GlaxoSmithKline (United Kingdom)), M. S. Berger(Duke University), Sandra Franco(Clínica Santa María)
Cited by 11
Related Papers
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
|The Lancet|2024|729
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
|Journal of Clinical Oncology|2007|483